Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Hutchison MediPharma’s Cancer Drug Begins Clinical Trials

publication date: May 3, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Hutchison MediPharma  announced dosing of the first patients in a Phase I clinical trial of its anti-cancer drug candidate, sulfatinib (HMPL-012). The SFDA granted approval of the trial in March, following an expedited Green Channel review of MediPharma’s investigational new drug application. MediPharma will test sulfatinib against solid tumors, particularly liver, gastric and renal cancer. More details...

Stock Symbol: (AIM: HCM)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...